How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

29,452 results for

Alcoholic Hepatitis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Evidence for a role of genetics in alcoholic hepatitis: Data from the STOPAH randomized controlled trial. (Abstract)

Evidence for a role of genetics in alcoholic hepatitis: Data from the STOPAH randomized controlled trial. 28412295 2018 12 14 2018 12 14 1600-0641 67 1 2017 07 Journal of hepatology J. Hepatol. Evidence for a role of genetics in alcoholic hepatitis: Data from the STOPAH randomized controlled trial. 12-14 S0168-8278(17)30210-6 10.1016/j.jhep.2017.04.001 Louvet Alexandre A Service des maladies de l'appareil digestif, Hôpital Huriez, Lille, France. Electronic address: alexandre.louvet@chru (...) -lille.fr. Peck-Radosavljevic Markus M Abteilung Gastroenterologie & Hepatologie, Endokrinologie und Nephrologie, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria. Electronic address: markus@peck.at. eng Editorial Comment 2017 04 13 Netherlands J Hepatol 8503886 0168-8278 IM J Hepatol. 2017 Jul;67(1):120-127 28161471 Hepatitis, Alcoholic Homozygote Humans 2017 03 14 2017 03 27 2017 04 04 2017 4 17 6 0 2018 12 15 6 0 2017 4 17 6 0 ppublish 28412295 S0168-8278(17)30210-6 10.1016/j.jhep.2017.04.001

2018 Journal of Hepatology Controlled trial quality: uncertain

162. Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial. Full Text available with Trip Pro

Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial. 29385313 2018 05 01 2018 12 02 1527-6473 24 5 2018 05 Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society Liver Transpl. Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial. 711 10.1002 (...) /lt.25026 Sussman Norman L NL Abdominal Transplant and Liver Disease Clinic, Baylor College of Medicine, Houston, TX. Kelly James H JH Cell Machines, Inc., Houston, TX. eng Letter Comment 2018 04 06 United States Liver Transpl 100909185 1527-6465 IM Liver Transpl. 2018 Mar;24(3):380-393 29171941 Hepatitis, Alcoholic Humans Liver Transplantation Prospective Studies 2017 12 25 2018 01 29 2018 2 1 6 0 2018 5 2 6 0 2018 2 1 6 0 ppublish 29385313 10.1002/lt.25026

2018 Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society Controlled trial quality: uncertain

163. Efficacy of granulocyte colony-stimulating factor therapy in patients with severe alcoholic hepatitis

Efficacy of granulocyte colony-stimulating factor therapy in patients with severe alcoholic hepatitis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2020 PROSPERO

164. A Validated Score Predicts Acute Kidney Injury and Survival in Patients With Alcoholic Hepatitis. (Abstract)

A Validated Score Predicts Acute Kidney Injury and Survival in Patients With Alcoholic Hepatitis. Identifying patients at high risk for acute kidney injury (AKI) during hospitalization among patients admitted with severe alcoholic hepatitis (AH) is an unmet clinical need. We performed a multicentric prospective cohort study using data from 4 different cohorts on well-characterized patients hospitalized with severe AH. Data collected on 773 AH patients from 4 cohorts across the globe were (...) randomly split into test (n = 390) and validation (n = 383) cohorts. We found that 32% of the patients developed inpatient AKI in the test cohort. Approximately 60% of patients met criteria for systemic inflammatory response syndrome (SIRS) at admission. Hepatic encephalopathy, SIRS, and Model for End-Stage Liver Disease score at admission predicted inpatient AKI with odds ratios of 3.86, 2.24, and 1.14, respectively. The AKI risk score developed using these predictors stratified risk of inpatient AKI

2018 Liver Transplantation

165. Health-related Quality of Life in Non-alcoholic Fatty Liver Disease Associates With Hepatic Inflammation. (Abstract)

Health-related Quality of Life in Non-alcoholic Fatty Liver Disease Associates With Hepatic Inflammation. Chronic liver disease has negative effects on health-related quality of life (HRQL). We analyzed data from the European non-alcoholic fatty liver disease (NAFLD) registry to assess the effects of NAFLD on HRQL.We collected data from 304 patients (mean age, 52.3±12.9 years) with histologically defined NAFLD enrolled prospectively into the European NAFLD Registry in Germany, the United (...) Kingdom, and Spain. The chronic liver disease questionnaire (CLDQ) was completed within 6 months of liver biopsy collection.The mean CLDQ overall score was 5.0±1.2, with the lowest score in the category fatigue (4.3±1.6) and the highest scores for activity (5.4±1.4). Women had significantly lower CLDQ scores than men (4.6±1.3 vs 5.3±1.1; P<.001). We found negative correlations between CLDQ scores and presence of obesity (P<.001), type 2 diabetes (P<.001), and dyslipidaemia (P<.01

2018 Clinical Gastroenterology and Hepatology

166. IL-1 Signal Inhibition in Alcoholic Hepatitis (ISAIAH)

mDF* ≥ 32 and MELD ≤ 25 at baseline visit Informed consent Women of child-bearing potential have to use an effective contraception method (as specified in section 9.6). Exclusion Criteria: Alcohol abstinence of >6 weeks prior to randomization/baseline visit Duration of clinically apparent jaundice > 3 months before baseline visit Other causes of liver disease including: Evidence of chronic viral hepatitis (Hepatitis B or C) Biliary obstruction Hepatocellular carcinoma Evidence of current (...) malignancy (except non-melanotic skin cancer) Previous entry into the study, or use of either prednisolone or PTX within 6 weeks of hospital admission AST >500 U/L or ALT >300 U/L (not compatible with alcoholic hepatitis) Patients with a serum creatinine >220 μmol/L (2.5 mg / dL) or requiring renal support (see below) Patients dependent upon inotropic support (adrenaline or noradrenaline). Terlipressin is allowed Variceal haemorrhage on this admission Untreated sepsis (see below) Patients with known

2018 Clinical Trials

167. Arid1a loss drives non-alcoholic steatohepatitis in mice via epigenetic dysregulation of hepatic lipogenesis and fatty acid oxidation. Full Text available with Trip Pro

Arid1a loss drives non-alcoholic steatohepatitis in mice via epigenetic dysregulation of hepatic lipogenesis and fatty acid oxidation. Nonalcoholic steatohepatitis (NASH) is a rapidly growing cause of chronic liver damage, cirrhosis, and hepatocellular carcinoma (HCC). How fatty liver pathogenesis is subject to epigenetic regulation is unknown. We hypothesized that chromatin remodeling is important for the pathogenesis of fatty liver disease. ARID1A, a DNA-binding component of the SWI/SNF ATP (...) -dependent chromatin-remodeling complex, contributes to nucleosome repositioning and access by transcriptional regulators. Liver-specific deletion of Arid1a (Arid1a LKO) caused the development of age-dependent fatty liver disease in mice. Transcriptome analysis revealed upregulation of lipogenesis and down-regulation of fatty acid oxidation genes. As evidence of direct regulation, ARID1A demonstrated direct binding to the promoters of many of these differentially regulated genes. Additionally, Arid1a LKO

2018 Hepatology

168. Ductular reaction cells display an inflammatory profile and recruit neutrophils in alcoholic hepatitis. (Abstract)

Ductular reaction cells display an inflammatory profile and recruit neutrophils in alcoholic hepatitis. Chronic liver diseases are characterized by the expansion of ductular reaction (DR) cells and the expression of liver progenitor cell (LPC) markers. In alcoholic hepatitis (AH), the degree of DR expansion correlates with disease progression and short-term survival. However, little is known about the biological properties of DR cells, their impact on the pathogenesis of human liver disease (...) , and their contribution to tissue repair. In this study, we have evaluated the transcriptomic profile of DR cells by laser capture microdissection in patients with AH and assessed its association with disease progression. The transcriptome analysis of cytokeratin 7-positive (KRT7+ ) DR cells uncovered intrinsic gene pathways expressed in DR and genes associated with alcoholic liver disease progression. Importantly, DR presented a proinflammatory profile with expression of neutrophil recruiting C-X-C motif chemokine

2018 Hepatology

169. Transplantation for Alcoholic Hepatitis: Are We Achieving Justice and Utility? (Abstract)

Transplantation for Alcoholic Hepatitis: Are We Achieving Justice and Utility? Early liver transplantation for alcoholic hepatitis is a potentially life-saving treatment. As this practice becomes increasingly common, however, the liver transplant community is taking a fresh look at a familiar challenge: best stewardship of donor organs. Herein, we examine a few basic, necessary ethical and practical concerns relevant to this indication.© 2018 by the American Association for the Study of Liver

2018 Hepatology

170. Efficacy of granulocyte colony stimulating factor in patients with severe alcoholic hepatitis with partial or null response to steroid (GRACIAH trial): study protocol for a randomized controlled trial. Full Text available with Trip Pro

Efficacy of granulocyte colony stimulating factor in patients with severe alcoholic hepatitis with partial or null response to steroid (GRACIAH trial): study protocol for a randomized controlled trial. Alcoholic hepatitis (AH) has the most severe presentation among alcohol-related liver diseases. Corticosteroids are the most widely recommended treatment for severe AH. However, more innovative, refined treatment measures are required because of its high mortality despite corticosteroid treatment

2018 Trials Controlled trial quality: uncertain

171. Noncholesterol Sterols as Surrogate Markers in Patients with Severe Alcoholic Hepatitis. (Abstract)

Noncholesterol Sterols as Surrogate Markers in Patients with Severe Alcoholic Hepatitis. Severe alcoholic hepatitis (AH) is a life-threatening condition lacking good serologic markers to tailor treatment and predict recovery. We examined the cholesterol metabolism in severe AH to explore prognostic markers and evaluate the profile of cholesterol precursors, cholestanol and phytosterols, in this context. We assessed serum cholesterol, cholesterol precursors, cholestanol, phytosterols

2018 Lipids Controlled trial quality: uncertain

172. Non‐alcoholic fatty liver disease in patients with autoimmune hepatitis Full Text available with Trip Pro

Non‐alcoholic fatty liver disease in patients with autoimmune hepatitis The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing all over the world. NAFLD develops in patients with liver disease, including patients with autoimmune hepatitis (AIH). NAFLD and AIH have some similar laboratory and histological findings. The aim of this study was to elucidate the characteristics of AIH patients with NAFLD.We re-evaluated the nationwide survey performed in Japan in 2015 of AIH (...) patients diagnosed between 2009 and 2013.A total of 1151 subjects (144 men and 1007 women) were enrolled in the present study. The overall prevalence of NAFLD was 17.0%. Compared to AIH without NAFLD, AIH patients with NAFLD had the following characteristics: (i) low female-to-male ratio, (ii) older age, (iii) mild elevation in hepatobiliary enzymes, (iv) histologically progressive fibrosis and mild plasma cell infiltration or mild lobular hepatitis, (v) lower prevalence of prednisolone administration

2018 JGH Open: An Open Access Journal of Gastroenterology and Hepatology

173. Early liver transplant for severe alcoholic hepatitis: establishing a new frontier by ignoring the rule? Full Text available with Trip Pro

Early liver transplant for severe alcoholic hepatitis: establishing a new frontier by ignoring the rule? 30498738 2018 12 07 2305-5839 6 20 2018 Oct Annals of translational medicine Ann Transl Med Early liver transplant for severe alcoholic hepatitis: establishing a new frontier by ignoring the rule? 411 10.21037/atm.2018.09.57 Zhu Julie J Division of Gastroenterology, University of British Columbia, Vancouver General Hospital, Vancouver, BC, Canada. Hussaini Trana T The Faculty

2018 Annals of Translational Medicine

174. Interaction between the patatin‐like phospholipase domain‐containing protein 3 genotype and coffee drinking and the risk for acute alcoholic hepatitis Full Text available with Trip Pro

Interaction between the patatin‐like phospholipase domain‐containing protein 3 genotype and coffee drinking and the risk for acute alcoholic hepatitis Only a subset of subjects with excessive alcohol consumption develops alcoholic liver disease (ALD). One of the major risk factors for ALD is the genetic variant of the patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene. Coffee is one of the most commonly consumed beverages, and coffee consumption has been associated (...) with lower levels of serum alanine aminotransferase. The aim of this study was to investigate the role of coffee drinking and PNPLA3 rs738409 and their association with alcoholic hepatitis (AH) in a well-characterized cohort of subjects from the Translational Research and Evolving Alcoholic Hepatitis Treatment consortium. AH subjects and heavy drinking controls without a history of liver disease who were enrolled between May 2013 and May 2016 were included (n = 339), and the details of alcohol and coffee

2017 Hepatology communications

175. Osteopontin deletion drives hematopoietic stem cell mobilization to the liver and increases hepatic iron contributing to alcoholic liver disease Full Text available with Trip Pro

Osteopontin deletion drives hematopoietic stem cell mobilization to the liver and increases hepatic iron contributing to alcoholic liver disease The aim of this study was to investigate the role of osteopontin (OPN) in hematopoietic stem cell (HPSC) mobilization to the liver and its contribution to alcoholic liver disease (ALD). We analyzed young (14-16 weeks) and old (>1.5 years) wild-type (WT) littermates and global Opn knockout (Opn-/- ) mice for HPSC mobilization to the liver. In addition (...) , WT and Opn-/- mice were chronically fed the Lieber-DeCarli diet for 7 weeks. Bone marrow (BM), blood, spleen, and liver were analyzed by flow cytometry for HPSC progenitors and polymorphonuclear neutrophils (PMNs). Chemokines, growth factors, and cytokines were measured in serum and liver. Prussian blue staining for iron deposits and naphthol AS-D chloroacetate esterase staining for PMNs were performed on liver sections. Hematopoietic progenitors were lower in liver and BM of young compared

2017 Hepatology communications

176. Alcoholic Hepatitis: Lost in Translation Full Text available with Trip Pro

Alcoholic Hepatitis: Lost in Translation Alcoholic hepatitis is the most severe and acute form of alcoholic liver disease. The mortality rate associated with alcoholic hepatitis is high, largely due to the lack of suitable pharmacological interventions. While there has been substantial research in the area, generating pharmacological interventions has been plagued by the lack of a robust mouse model both for testing and for understanding the underlying pathology. A number of major notable (...) advances have been made in this area recently, with the goal of generating a mouse model of alcoholic hepatitis. The purpose of this article is to review recent advances in modeling alcoholic liver disease both in vitro and in vivo in the mouse, and place them in the context of the greater spectrum of alcoholic liver disease, with a focus on how we can translate current advances into a high-fidelity model of alcoholic hepatitis. In addition, we will review the basic mechanisms of alcoholic hepatitis

2017 Journal of clinical and translational hepatology

177. Prediction of histologic alcoholic hepatitis based on clinical presentation limits the need for liver biopsy Full Text available with Trip Pro

Prediction of histologic alcoholic hepatitis based on clinical presentation limits the need for liver biopsy The clinical presentation of alcoholic hepatitis (AH) can be mimicked by other alcoholic liver diseases. The aim of this study was to identify clinical features that predict AH on liver biopsy. Biopsies from patients hospitalized for presumed severe AH were used to identify a derivation cohort (101 patients) and validation cohort (71 patients). Using histologic scores for hepatocyte (...) characteristic curve of 0.72. Conclusion: The combination of an elevated leukocyte count and a nodular liver surface in the absence of active infection retrospectively identified patients with a high likelihood of histologic AH for whom liver biopsy may not be necessary. For patients with suspected severe AH who do not fulfill these criteria, liver biopsy is important to exclude other variants of alcoholic liver disease. (Hepatology Communications 2017;1:1070-1084).

2017 Hepatology communications

178. Role of gp91phox in hepatic macrophage programming and alcoholic liver disease Full Text available with Trip Pro

Role of gp91phox in hepatic macrophage programming and alcoholic liver disease Hepatic macrophages (MΦs) are important in the development and progression of alcoholic liver disease (ALD). This study investigates the role of gp91phox (nicotinamide adenine dinucleotide phosphate oxidase 2) in the severity of ALD and specifically in regulating hepatic MΦ efferocytic capability and the subsequent reprogramming associated with resolution of inflammation. After 4 weeks of ethanol feeding, more severe (...) ALD developed in gp91phox-/- mice than in wild-type (WT) C57Bl/6J mice, evidenced by increased liver injury and inflammation. This phenomenon was not sex dependent, and thus the majority of experiments were performed with female mice. While total hepatic MΦ numbers did not differ between genotypes, hepatic infiltrating MΦs (IMs) were slightly more numerous in gp91phox-/- mice, and both IMs and resident Kupffer cells displayed enhanced proinflammatory and reduced tissue-restorative programming

2017 Hepatology communications

179. Severe Alcoholic Hepatitis: Atypical Presentation with Markedly Elevated Alkaline Phosphatase Full Text available with Trip Pro

Severe Alcoholic Hepatitis: Atypical Presentation with Markedly Elevated Alkaline Phosphatase Alcoholic hepatitis (AH) is an acute inflammatory liver disease with poor prognosis. Infections in AH are difficult to detect and contribute to short-term mortality. Intrahepatic cholestasis and elevated alkaline phosphatase levels are also associated with worse outcomes. This report describes an uncommon presentation of severe AH.

2017 Journal of clinical and translational hepatology

180. Application of prognostic scores in the STOPAH trial: Discriminant function is no longer the optimal scoring system in alcoholic hepatitis. Full Text available with Trip Pro

Application of prognostic scores in the STOPAH trial: Discriminant function is no longer the optimal scoring system in alcoholic hepatitis. 'Static' prognostic models in alcoholic hepatitis, using data from a single time point, include the discriminant function (DF), Glasgow alcoholic hepatitis score (GAHS), the age, serum bilirubin, international normalized ratio and serum creatinine (ABIC) score and the model of end-stage liver disease (MELD). 'Dynamic' scores, incorporating evolution (...) = 0.02; GAHS 21% vs. 29.3%, p = 0.04). Overall mortality from treating all patients with a DF ≥32 and Lille assessment (90-day mortality 26.8%) was greater than combining newer 'static' and 'dynamic' scores (90-day mortality: MELD/Lille 21.8%; ABIC/Lille 23.7%; GAHS/Lille 20.6%).MELD, ABIC and GAHS are superior to the DF in alcoholic hepatitis. Consistently low scores have a favourable outcome not improved with prednisolone. Combined baseline 'static' and Day 7 scores reduce the number of patients

2018 Journal of Hepatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>